Mouse EphB4 Antibody

R&D Systems | Catalog # AF446

R&D Systems

Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Mouse

Cited:

Human, Mouse, Rat, Fish - Danio rerio (Zebrafish), Primate - Chlorocebus aethiops (African Green Monkey)

Applications

Validated:

Immunohistochemistry, Western Blot, Flow Cytometry, CyTOF-ready

Cited:

Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Western Blot, Flow Cytometry, Immunofluorescence, Immunoprecipitation, Bioassay

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG
Loading...

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant mouse EphB4
Leu16-Ala539
Accession # P54761

Specificity

Detects mouse EphB4 in direct ELISAs and Western blots. In direct ELISAs, approximately 5% cross-reactivity with recombinant mouse (rm) EphB6 and rmEphA3 is observed and less than 1% cross-reactivity with rmEphA2, rmEphA4, rmEphA6, rmEphA7, rmEphA8, rmEphB2, and rmEphB3 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Mouse EphB4 Antibody

EphB4 antibody in Mouse Embryo by Immunohistochemistry (IHC-Fr).

EphB4 in Mouse Embryo.

EphB4 was detected in immersion fixed frozen sections of mouse embryo (15 d.p.c.) using Goat Anti-Mouse EphB4 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF446) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Frozen Tissue Sections.
Detection of Mouse EphB4 by Western Blot

Detection of Mouse EphB4 by Western Blot

Reduced Eph-B4 activity increases venous neointimal thickening. (A) Representative photomicrographs (left panel) and bar graph (right panel) showing AVF venous limb wall thickness in control and Eph-B4 het mice (day 21); *P = 0.047 (t-test). n = 8. Scale bar 25 µm. (B) Line graph showing infrarenal IVC diameter in control or Eph-B4 het mice; *P = 0.59 (ANOVA). n = 8–9. (C) Representative Western blot showing inhibited tyrosine phosphorylation in the Y774F-Eph-B4 mutant compared to the WT-Eph-B4 construct (0–60 min). (D) Bar graph showing Ephrin-B2/Fc stimulated COS cell migration after transfection with WT-Eph-B4 or Y774F-Eph-B4 plasmids. P < 0.0001 (ANOVA); *P < 0.0001 Ephrin-B2/Fc WT-Eph-B4 vs Y774F-Eph-B4. n = 3–4. (E) Representative photomicrographs (left panel) showing AVF venous wall (elastin stain) in control mice or mice treated with WT-Eph-B4 or mutant Y774F-Eph-B4. Arrow heads denote neointimal thickness. Scale bar, 25 µm. Bar graph (right panel) showing quantification of AVF venous wall thickness in control mice (white bar) or mice treated with WT-Eph-B4 (gray bar) or mutant Y774F-Eph-B4 (blue bar), day 21; P = 0.035 (ANOVA). *P = 0.038 (WT-Eph-B4 vs Y774F-Eph-B4; post hoc). n = 5–7. (F) Line graph showing infrarenal IVC diameter in mice with AVF treated with WT-Eph-B4 (gray line) or mutant Y774F-Eph-B4 (purple line) compared to control (black line); *P = 0.005 (ANOVA). n = 5–11. Data represent mean ± SEM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29133876), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human EphB4 by Western Blot

Detection of Human EphB4 by Western Blot

Increased Eph-B4 and Ephrin-B2 expression during adaptive venous remodeling. (A) Western blot and adjacent bar graph of densitometry showing human Eph-B4 expression in AVF venous limb compared to normal vein. *P = 0.0016; t-test. n = 3–4. (B) Line graphs show expression of Eph-B4 (blue) and Ephrin-B2 (red) in the AVF venous limb compared to sham IVC; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0123, Eph-B4; P = 0.0041, Ephrin-B2; post hoc); **P < 0.05 (P < 0.0001, Ephrin-B2; post hoc). n = 5–8. (C) Western blots showing Eph-B4 and Ephrin-B2 protein expression in AVF venous limb compared to sham IVC. n = 3–5. (D) Graphs showing densitometry of Eph-B4 (left panel) and Ephrin-B2 (right panel) expression in the AVF venous limb compared to sham IVC; *P < 0.05 (P < 0.0001, Eph-B4 day 7, AVF vs sham; P < 0.0001, Eph-B4 day 21, AVF vs sham; P < 0.0001, Ephrin-B2 day 7, AVF vs sham; post hoc). n = 3–5. (E) Diagram of rat model showing location of infrarenal IVC pericardial patch exposed to an aortocaval AVF (n = 6 per group). (F) Representative Western blot (upper panel) showing Eph-B4 and Ephrin-B2 expression in patch neointima (day 14) of control vein compared to patch neointima of AVF vein. Graphs (lower panel) show quantification of western blot bands; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0003, Eph-B4; P = 0.0043, Ephrin-B2; post hoc). n = 3. (G) Representative photomicrographs (upper panel) showing Eph-B4 (green) and Ephrin-B2 (red) immunoreactive signal (day 14). White arrowheads indicate colocalization of Eph-B4 and Ephrin-B2. L, vessel lumen. Graph (lower panel) shows quantification of immunoreactive signal; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0136 Eph-B4; P < 0.0001 Ephrin-B2; post hoc). n = 3. Scale bar 100 µm. Data represent mean ± SEM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29133876), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human EphB4 by Western Blot

Detection of Human EphB4 by Western Blot

Increased Eph-B4 and Ephrin-B2 expression during adaptive venous remodeling. (A) Western blot and adjacent bar graph of densitometry showing human Eph-B4 expression in AVF venous limb compared to normal vein. *P = 0.0016; t-test. n = 3–4. (B) Line graphs show expression of Eph-B4 (blue) and Ephrin-B2 (red) in the AVF venous limb compared to sham IVC; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0123, Eph-B4; P = 0.0041, Ephrin-B2; post hoc); **P < 0.05 (P < 0.0001, Ephrin-B2; post hoc). n = 5–8. (C) Western blots showing Eph-B4 and Ephrin-B2 protein expression in AVF venous limb compared to sham IVC. n = 3–5. (D) Graphs showing densitometry of Eph-B4 (left panel) and Ephrin-B2 (right panel) expression in the AVF venous limb compared to sham IVC; *P < 0.05 (P < 0.0001, Eph-B4 day 7, AVF vs sham; P < 0.0001, Eph-B4 day 21, AVF vs sham; P < 0.0001, Ephrin-B2 day 7, AVF vs sham; post hoc). n = 3–5. (E) Diagram of rat model showing location of infrarenal IVC pericardial patch exposed to an aortocaval AVF (n = 6 per group). (F) Representative Western blot (upper panel) showing Eph-B4 and Ephrin-B2 expression in patch neointima (day 14) of control vein compared to patch neointima of AVF vein. Graphs (lower panel) show quantification of western blot bands; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0003, Eph-B4; P = 0.0043, Ephrin-B2; post hoc). n = 3. (G) Representative photomicrographs (upper panel) showing Eph-B4 (green) and Ephrin-B2 (red) immunoreactive signal (day 14). White arrowheads indicate colocalization of Eph-B4 and Ephrin-B2. L, vessel lumen. Graph (lower panel) shows quantification of immunoreactive signal; P < 0.0001 (ANOVA). *P < 0.05 (P = 0.0136 Eph-B4; P < 0.0001 Ephrin-B2; post hoc). n = 3. Scale bar 100 µm. Data represent mean ± SEM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29133876), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of EphB4 by Immunohistochemistry

Detection of EphB4 by Immunohistochemistry

Immunofluorescent analysis of vascular networks in the pituitary posterior lobe. (A-C) Immunofluorescent analysis for Isolectin B4 (red) (A, B and C), Dll4 (green) (A), EphB2 (green) (B), EphB4 (green) (B), Notch4 (green) (C) and PLVAP (blue) (A). Larger radius vessels strongly labeled with Isolectin B4 are Dll4-positive (arrows) and PLVAP-negative (arrow heads) (A), EphB2-negative (arrow heads) and EphB4-negative (arrow heads) (B). (C) shows that Notch4 expressed in Isolectin B4-positive vessels in the pituitary posterior lobe but not in Notch4 KO mice. Scale bars = 50 μm (A, B and C). Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41598-025-17225-5), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of EphB4 by Immunohistochemistry

Detection of EphB4 by Immunohistochemistry

EphB4 signaling in PF.(A and B) Human IPF lung fibroblasts were treated with TGF-beta 1 or PBS for 24 hours. Cells (total 16 samples; n = 4 patients/group) were then treated with either NVP-BHG712 (250 nM) (A) or Ephb4 siRNA (B), or their respective controls, for an additional 24 hours. Protein lysates were collected, and Western blotting was performed to detect ELN protein levels. ImageJ densitometry was performed and normalized to GAPDH (mean ± SD). *P < 0.05; **P < 0.01, as determined by paired 2-way ANOVA followed by Tukey’s post hoc test adjusted for multiple comparisons. (C) Western blotting of siRNA treated IPF cells to detect P-SMAD 2/3 and total SMAD 2/3 (n = 4/group). (D and E) Verhoeff Van Gieson staining was performed on lung sections from mice with Ephb4 conditional knockout or respective control mice to visualize ELN (n = 5/group) following bleomycin or PBS instillation (D), or mice with bleomycin or PBS instillation treated with EphB4 inhibitor NVP-BHG712 (10 mg/kg) or vehicle (n = 5/group) (E). ELN staining was semiquantitatively scored (scores 0–3). ****P < 0.0001 as determined by 2-way ANOVA followed by Tukey’s post hoc tests adjusted for multiple comparisons. (F) Schematic depicting the role of EphB4 signaling in PF. Image collected and cropped by CiteAb from the following open publication (https://insight.jci.org/articles/view/189156), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of EphB4 by Western Blot

Detection of EphB4 by Western Blot

Preserved protein stability with compromised tyrosine kinase activity in EPHB4 kinase domain variants.a Steady-state abundance of EPHB4 D-mis mutants. Cos-7 cells were transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants together with an eGFP-encoding vector. Numbers at top indicate percentage of GFP+ cells determined by flow cytometry (see Supplementary Fig. 3). Cells were lysed and EPHB4 abundance determined by Western blot for c-myc (left) or EPHB4 (right). Blots were probed for tubulin or beta actin (ActB) respectively to demonstrate equivalent protein loading. Numbers below indicate normalized abundance of EPHB4 D-mis mutants relative to WT EPHB4. Each experiment was repeated two times with similar results. b Stability of EPHB4 D-mis mutants. Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants were treated with cycloheximide (CHX) for the indicated times before lysis and determination of EPHB4 and ActB abundance by Western blot. Numbers indicate normalized EPHB4 abundance relative to CHX-untreated cells for each time point. Shown are the results of a single experiment. c Kinase activity of EPHB4 D-mis mutants. EPHB4 was immunoprecipitated from Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants. EPHB4 kinase activity was determined by Western blot of immunoprecipitates with an anti-phosphotyrosine antibody (pTyr). Numbers indicate normalized pTyr content of EPHB4 D-mis mutants relative to WT EPHB4. Shown are the results of one experiment of two repeats. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37978175), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of EphB4 by Western Blot

Detection of EphB4 by Western Blot

Preserved protein stability with compromised tyrosine kinase activity in EPHB4 kinase domain variants.a Steady-state abundance of EPHB4 D-mis mutants. Cos-7 cells were transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants together with an eGFP-encoding vector. Numbers at top indicate percentage of GFP+ cells determined by flow cytometry (see Supplementary Fig. 3). Cells were lysed and EPHB4 abundance determined by Western blot for c-myc (left) or EPHB4 (right). Blots were probed for tubulin or beta actin (ActB) respectively to demonstrate equivalent protein loading. Numbers below indicate normalized abundance of EPHB4 D-mis mutants relative to WT EPHB4. Each experiment was repeated two times with similar results. b Stability of EPHB4 D-mis mutants. Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants were treated with cycloheximide (CHX) for the indicated times before lysis and determination of EPHB4 and ActB abundance by Western blot. Numbers indicate normalized EPHB4 abundance relative to CHX-untreated cells for each time point. Shown are the results of a single experiment. c Kinase activity of EPHB4 D-mis mutants. EPHB4 was immunoprecipitated from Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants. EPHB4 kinase activity was determined by Western blot of immunoprecipitates with an anti-phosphotyrosine antibody (pTyr). Numbers indicate normalized pTyr content of EPHB4 D-mis mutants relative to WT EPHB4. Shown are the results of one experiment of two repeats. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37978175), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of EphB4 by Western Blot

Detection of EphB4 by Western Blot

Preserved protein stability with compromised tyrosine kinase activity in EPHB4 kinase domain variants.a Steady-state abundance of EPHB4 D-mis mutants. Cos-7 cells were transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants together with an eGFP-encoding vector. Numbers at top indicate percentage of GFP+ cells determined by flow cytometry (see Supplementary Fig. 3). Cells were lysed and EPHB4 abundance determined by Western blot for c-myc (left) or EPHB4 (right). Blots were probed for tubulin or beta actin (ActB) respectively to demonstrate equivalent protein loading. Numbers below indicate normalized abundance of EPHB4 D-mis mutants relative to WT EPHB4. Each experiment was repeated two times with similar results. b Stability of EPHB4 D-mis mutants. Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants were treated with cycloheximide (CHX) for the indicated times before lysis and determination of EPHB4 and ActB abundance by Western blot. Numbers indicate normalized EPHB4 abundance relative to CHX-untreated cells for each time point. Shown are the results of a single experiment. c Kinase activity of EPHB4 D-mis mutants. EPHB4 was immunoprecipitated from Cos-7 cells transiently transfected with c-myc-tagged WT or EPHB4 D-mis mutants. EPHB4 kinase activity was determined by Western blot of immunoprecipitates with an anti-phosphotyrosine antibody (pTyr). Numbers indicate normalized pTyr content of EPHB4 D-mis mutants relative to WT EPHB4. Shown are the results of one experiment of two repeats. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37978175), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of EphB4 by Western Blot

Detection of EphB4 by Western Blot

Interplay of EphB4, ephrin-B2 and SoxF factors.a–d Confocal images and quantitation of Sox17 immunostaining in retinal sprouts (b) and artery (b, d) (n = 5 control and 5 Ephb4i delta EC and n = 5 control and 5 Efnb2i delta EC) and percentage of cells with high Sox17 immunosignal vs total ECs (n = 3 control and 3 Ephb4i delta EC and n = 3 control and 3 Efnb2i delta EC) (b, d). e Violin plots of SOX7, SOX17 and SOX18 gene expression from scRNA-seq experiment comparing siControl and siEPHB4 cells. f SoxF factors reduce EPHB4 and increase EFNB2 transcripts (n = 3 experiments). g, h Immunoblot analysis and quantitation of EphB4 and ephrin-B2 protein upon SOX7 + SOX17 + SOX18 knockdown (n = 3 experiments). i Genome localization of Sox18 putative motifs in EFNB2 and EPHB4 human genes selected for further investigation. j Quantitation graphs for luciferase activity of putative binding regions of Sox18 on EFNB2 and EPHB4 showing direct regulation of EFNB2 expression via Sox18 in two regions (n = 3 experiments). k Increased luciferase activity upon EPHB4 KD compared to siControl for Sox18 binding regions on EFNB2 (n = 3 experiments). l Sox17 expression in ephrin-B2+ sprouts (single confocal z-plane). IB4, GFP and Sox17 staining in P6 Efnb2-H2B-GFP knock-in reporter retinal vasculature. m Graph indicating proportion of Sox17+ cells in ephrin-B2+ tip cells (n = 3 Efnb2-GFP mice). n Schematic representation of interactions between Sox17, ephrin-B2 and EphB4. P values were calculated using two-tailed unpaired t test (b, d, f, h) and one-way ANOVA (j,k). In vivo experiments were performed with tamoxifen injections at P1-P3 and analysis at P6 (a, c). Data are presented as mean values ± SEM. Source data are provided as a Source Data file. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41467-024-46300-0), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of EphB4 by Immunohistochemistry

Detection of EphB4 by Immunohistochemistry

VOGM-specific EPHB4 variant disrupts developmental angiogenesis.Ephb4+/F867L mice were intercrossed. a Number of live born Ephb4+/+ wild-type (WT), Ephb4+/F867L heterozygote (Het), and Ephb4F867L/F867L homozygote (Hom) mice. **p = 0.0046; Chi-squared test (two-sided). b Images of littermate embryos of the indicated genotypes at E10.5. Note abnormal vascularization of the yolk sac, reduced size and distended pericardial sac (arrow) of homozygous Ephb4F867L/F867L embryos. c Mean +/- 1 SEM of embryo length at E10.5 (WT, n = 10; Het, n = 18; Hom, n = 8). ****P < 0.0001; ns, not significant; Student’s two-sample two-sided t-test. d E10.5 yolk sacs were stained with anti-CD31 antibodies to identify vasculature. Images at right are higher magnifications of the boxed areas of images at left. Note hierarchical vascular networks in yolk sacs of wild-type and heterozygous embryos and primitive vascular plexuses in yolk sacs of homozygous Ephb4F867L/F867L embryos that present as classical honeycomb-like structures at higher magnification. e CD31 antibody staining of E9.5 embryos of the indicated genotypes. For each embryo, the right image is a higher magnification of the boxed area in the left image. Arrows show trunk angiogenesis toward the midline in wild-type and heterozygous embryos but not homozygous Ephb4F867L/F867L embryos. Images in (d, e) are representative of at least 2 embryos of each genotype. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37978175), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of EphB4 by Immunohistochemistry

Detection of EphB4 by Immunohistochemistry

Ephrin-B2 and EphB4 regulate EC segregation and artery formation.a Homotypic or heterotypic co-culture of HUVECs and HUAECs, as indicated. Final snapshots of CellTracker-labeled cells imaged for 48 h after removal of Ibidi insert. Quantitation graph for relative border length (n = 3 experiments). b RT-qPCR for EPHB4 and EFNB2 in HUVECs and HUAECs (n = 3 experiments). c, d EphB4 restrains while ephrin-B2 promotes artery growth. High-magnification confocal images of IB4 and GFP stained P6 retinal vasculature (n = 6 control and Ephb4i delta TC mice (c) and n = 6 control and 4 Efnb2i delta TC mice (d)). e, f Quantitation of the GFP+ area (Esm1-derived progeny) in capillary plexus, front and artery per total GFP positive area (n = 6 control and Ephb4i delta TC mice (e) and n = 6 control and 4 Efnb2i delta TC mice (f )). g, h Arteries in Ephb4i delta TC mice are longer and have more branches, while both parameters are reduced in Efnb2i delta TC mice. Graphs show number of arterial branches and artery extension relative to vascular plexus extension (n = 9 control and 8 Ephb4i delta TC mice (g) and n = 6 control and 4 Efnb2i delta TC mice (h)). i Representative images of Ephb4i delta TC retinas with arterial alterations compared to control. Graph shows quantitation of AV retinal crossings, overextended arterial side branches and normal vascular morphology (n = 17 control and 17 Ephb4i delta TC). j Scheme depicting that ephrin-B2-EphB4 interaction and correct levels are required for proper artery formation. P values were calculated by one-way ANOVA (a), two-tailed unpaired t test (b–h) and Chi-square test (i). In vivo experiments were performed with tamoxifen injections from P1-P3 with analysis at P6 (c, d, g–i). Data are presented as mean values ± SEM. Source data are provided as a Source Data file. Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41467-024-46300-0), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Mouse EphB4 Antibody

Application
Recommended Usage

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

2.5 µg/106 cells
Sample: MCF‑7 human breast cancer cell line

Immunohistochemistry

5-15 µg/mL
Sample: Immersion fixed frozen sections of mouse embryo (E13-15)

Western Blot

0.1 µg/mL
Sample: Recombinant Mouse EphB4 Fc Chimera (Catalog # 446-B4)

Reviewed Applications

Read 4 reviews rated 4.3 using AF446 in the following applications:

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

  • Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
  • Spillover Popups - Visualize the spectra of individual fluorochromes
  • Antigen Density Selector - Match fluorochrome brightness with antigen density
Build Your Panel Now

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.


Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: EphB4

EphB4, also known as Htk, Myk1, Tyro11, and Mdk2 (1), is a member of the Eph receptor family which binds members of the ephrin ligand family. There are two classes of receptors, designated A and B. Both the A and B class receptors have an extracellular region consisting of a globular domain, a cysteine-rich domain, and two fibronectin type III domains. This is followed by the transmembrane region and cytoplasmic region. The cytoplasmic region contains a juxtamembrane motif with two tyrosine residues, which are the major autophosphorylation sites, a kinase domain, and a conserved sterile alpha motif (SAM) in the carboxy tail which contains one conserved tyrosine residue. Activation of kinase activity occurs after ligand recognition and binding. EphB4 has been shown to bind ephrin‑B2 and ephrin‑B1 (2, 3). The extracellular domains of human and mouse EphB4 share 88% amino acid identity. Only membrane-bound or Fc-clustered ligands are capable of activating the receptor in vitro. While soluble monomeric ligands bind the receptor, they do not induce receptor autophosphorylation and activation (2). In vivo, the ligands and receptors display reciprocal expression (3). It has been found that nearly all receptors and ligands are expressed in developing and adult neural tissue (3). The Eph/ephrin families also appear to play a role in angiogenesis (3).

References

  1. Eph Nomenclature Committee [letter] (1997) Cell 90:403.
  2. Flanagan, J.G. and P. Vanderhaeghen (1998) Annu. Rev. Neurosci. 21:309.
  3. Pasquale, E.B. (1997) Curr. Opin. Cell Biol. 9:608.

Long Name

Eph Receptor B4

Alternate Names

Htk, Mdk2, Myk1, Tyro11

Entrez Gene IDs

2050 (Human); 13846 (Mouse)

Gene Symbol

EPHB4

UniProt

Additional EphB4 Products

Product Documents for Mouse EphB4 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.


Can't find your language? Request a SDS in your language here.

Product Specific Notices for Mouse EphB4 Antibody

For research use only

Citations for Mouse EphB4 Antibody

Customer Reviews for Mouse EphB4 Antibody (4)

4.3 out of 5
4 Customer Ratings
5 Stars
50%
4 Stars
25%
3 Stars
25%
2 Stars
0%
1 Stars
0%

Have you used Mouse EphB4 Antibody?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 for a review with an image

$10/€7/£6/$10CAN/¥1110 for a review without an image

Submit a review
Amazon Gift Card

Customer Images


Showing  1 - 4 of 4 reviews Showing All
Filter By:
  • Mouse EphB4 Antibody
    Name: Anonymous
    Application: Immunocytochemistry/Immunofluorescence
    Sample Tested: E12.5 mouse embryo fixed in 4% PFA
    Species: Mouse
    Verified Customer | Posted 12/16/2020
    Dilution used - 1:200. The staining was done on an E12.5 transverse (4% PFA fixed) mouse section using standard IF techniques. Used 1% BSA for blocking for 1 hour before adding the primary antibody. The results are hit or miss for me, because I have noticed expression on non target tissue (Sometimes it doesn't appear, sometimes it does). Attached pictures shows a artery (smaller circle) and a vein (bigger circle), and while the EphB4 expression on the vein is very good (as it is supposed to express there), there seems to be some non-specific expression on the adjacent artery as well.
    Mouse EphB4 Antibody AF446
  • Mouse EphB4 Antibody
    Name: Anonymous
    Application: Western Blot
    Sample Tested: embryos
    Species: Zebrafish
    Verified Customer | Posted 11/13/2020
    Mouse EphB4 Antibody AF446
  • Name: Anonymous
    Application: Western Blot
    Sample Tested: See PMID 22398409
    Species: Rat
    Verified Customer | Posted 01/08/2015
  • Name: Anonymous
    Application: Immunofluorescence
    Sample Tested: See PMID 22398409
    Species: Rat
    Verified Customer | Posted 01/08/2015

There are no reviews that match your criteria.

Showing  1 - 4 of 4 reviews Showing All

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies
Loading...